Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M223,250Revenue $M58,831Net Margin (%)19.0Z-Score3.4
Enterprise Value $M232,516EPS $3.7Operating Margin %20.7F-Score6
P/E(ttm))22.6Cash Flow Per Share $0Pre-tax Margin (%)22.1Higher ROA y-yY
Price/Book3.210-y EBITDA Growth Rate %-0.5Quick Ratio1.1Cash flow > EarningsY
Price/Sales3.85-y EBITDA Growth Rate %-6.4Current Ratio1.4Lower Leverage y-yN
Price/Cash Flow0y-y EBITDA Growth Rate %6.8ROA % (ttm)8.5Higher Current Ratio y-yY
Dividend Yield %3.0Insider Buy (3m)0ROE % (ttm)15.0Less Shares Outstanding y-yY
Payout Ratio %66.0Shares Outstanding M2,419ROI % (ttm)0Gross Margin Increase y-yN

Gurus Latest Trades with NVS

Number of guru portfolios checked: 84. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
NVSLee Ainslie 2014-09-30 Buy 0.38%$85.25 - $94.8
($90.27)
$ 92.292%New holding, 272570 sh.272,570
NVSRuane Cunniff 2014-09-30 Buy $85.25 - $94.8
($90.27)
$ 92.292%New holding, 7772 sh.7,772
NVSHOTCHKIS & WILEY 2014-09-30 Reduce-0.21%$85.25 - $94.8
($90.27)
$ 92.292%Reduce -98.51%9,646
NVSPRIMECAP Management 2014-09-30 Reduce-0.16%$85.25 - $94.8
($90.27)
$ 92.292%Reduce -6.74%22,239,448
NVSDodge & Cox 2014-06-30 Add0.4%$82.51 - $90.98
($87.73)
$ 92.295%Add 10.04%51,102,219
NVSHOTCHKIS & WILEY 2014-06-30 Reduce-0.52%$82.51 - $90.98
($87.73)
$ 92.295%Reduce -71.8%649,519
NVSLee Ainslie 2014-06-30 Sold Out -0.42%$82.51 - $90.98
($87.73)
$ 92.295%Sold Out0
NVSLee Ainslie 2014-03-31 Add0.1%$78.2 - $83.82
($81.23)
$ 92.2914%Add 31.52%351,580
NVSPRIMECAP Management 2014-03-31 Reduce-0.26%$78.2 - $83.82
($81.23)
$ 92.2914%Reduce -10.13%24,014,586
NVSLee Ainslie 2013-12-31 Reduce-0.56%$72.96 - $80.39
($77.55)
$ 92.2919%Reduce -66.76%267,321
NVSChris Davis 2013-09-30 Sold Out -0.01%$70.66 - $77.08
($73.84)
$ 92.2925%Sold Out0
NVSLee Ainslie 2013-06-30 Add0.2%$68.42 - $75.5
($72.61)
$ 92.2927%Add 39.5%741,689
NVSJohn Hussman 2013-06-30 Reduce-0.52%$68.42 - $75.5
($72.61)
$ 92.2927%Reduce -47.49%218,900
NVSVanguard Health Care Fund 2013-06-30 Sold Out -0.2%$68.42 - $75.5
($72.61)
$ 92.2927%Sold Out0
NVSLee Ainslie 2013-03-31 Buy 0.49%$63.3 - $71.32
($67.87)
$ 92.2936%New holding, 531689 sh.531,689
NVSVanguard Health Care Fund 2013-03-31 Reduce-0.71%$63.3 - $71.32
($67.87)
$ 92.2936%Reduce -85.39%726,200
NVSIrving Kahn 2013-03-31 Reduce-0.1%$63.3 - $71.32
($67.87)
$ 92.2936%Reduce -21.03%33,456
NVSDodge & Cox 2012-12-31 Add0.11%$58.97 - $63.96
($61.79)
$ 92.2949%Add 2.65%48,438,459
NVSKen Fisher 2012-09-30 Buy 0.86%$55.24 - $61.51
($58.49)
$ 92.2958%New holding, 5086362 sh.5,086,362
NVSDodge & Cox 2012-09-30 Add0.12%$55.24 - $61.51
($58.49)
$ 92.2958%Add 3.23%47,187,759
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

NVS is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
NVS Ruane Cunniff 2014-09-307,77200New Buy
NVS Lee Ainslie 2014-09-30272,5700.010.38New Buy
NVS Irving Kahn 2014-09-3030,36800.46+15.17%
NVS Ken Fisher 2014-09-306,015,2330.251.2+0.76%
NVS John Hussman 2014-09-30214,0000.011.7
NVS Dodge & Cox 2014-09-3050,905,4492.14.6-0.39%
NVS Mario Gabelli 2014-09-3010,19000.01-0.49%
NVS Jean-Marie Eveillard 2014-09-3012,84800-1.62%
NVS Tweedy Browne 2014-09-30283,9830.010.62-1.68%
NVS PRIMECAP Management 2014-09-3022,239,4480.922.2-6.74%
NVS HOTCHKIS & WILEY 2014-09-309,64600-98.51%
Premium Most recent portfolio changes are included for Premium Members only!


NVS: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Novartis Bioventures Ltd10% Owner 2014-09-22Buy325,000$15511view

Press Releases about NVS :

    Quarterly/Annual Reports about NVS:

      News about NVS:

      Articles On GuruFocus.com
      Dividend Aristocrats In Focus Part 52 of 54: Johnson & Johnson Dec 03 2014 
      Kahn Brothers' Third Quarter Numbers Nov 07 2014 
      Tweedy Browne Global Reports its Top Five Picks of Q3 Oct 21 2014 
      Zoetis Will Benefit from Industry Trends Oct 07 2014 
      International Securities For A Diversified Income Portfolio Sep 23 2014 
      Widely Held Guru Stocks Trading In Europe Sep 22 2014 
      Why Investing Internationally Can Help Your Portfolio Sep 12 2014 
      Weekly 52-Week Highs Highlight: LLY, BG, NVS, HRL Sep 07 2014 
      Sarah Ketterer’s Causeway International Value Fund Reports Top Five Aug 31 2014 
      I Am Sure This Pharma-Company Suits Your Portfolio Aug 28 2014 

      More From Our Partners
      Teva's (TEVA) 2015 Guidance Hit By Generics - Analyst Blog Dec 12 2014 - ZACKS

      More From Other Websites
      1:34 am Novartis gains FDA approval for Signifor LAR to treat patients with acromegaly, a rare and... Dec 16 2014
      Is This The Future Of Late-Stage Drug Development? Dec 15 2014
      Teva Upgraded On Strength Of Copaxone MS Drug Dec 12 2014
      Novartis announces results of trial evaluating the use of Afinitor® in first-line treatment in... Dec 12 2014
      Head-to-head psoriasis study demonstrates superiority of Novartis Cosentyx(TM) to Stelara® in... Dec 12 2014
      The Zacks Analyst Blog Highlights: Novartis, Amgen, Incyte and Allergan Dec 10 2014
      Amgen Successfully Expands Xgeva Label in the U.S. Dec 09 2014
      Novartis Reports Encouraging Data on Biosimilar of Neupogen Dec 09 2014
      Novartis (NVS) Presents Additional Data on Leukemia Drug Dec 08 2014
      Novartis announces safety and efficacy benefit of Jakavi® in global clinical trial of over 1,000... Dec 08 2014
      Novartis copy of Amgen biotech drug shows similar efficacy-study Dec 08 2014
      Novartis highlights new CTL019 clinical data showing complete remissions in children and young... Dec 06 2014
      Using Re-Engineered Immune Cells to Kill Leukemia Induces Lasting Remissions Dec 06 2014
      Array BioPharma Regains Binimetinib Rights from Novartis Dec 04 2014
      Array BioPharma: When Losing a Partnership Is Good News Dec 04 2014
      PVH shares slip on outlook, Aeropostale’s drop Dec 03 2014
      Array To Regain Worldwide Rights To Binimetinib Dec 03 2014
      Array Biopharma Regains Rights to Cancer Drug From Novartis Dec 03 2014
      A simple accessibility app can make the visual world audible Dec 02 2014
      Alexandria Real Estate REIT Inks Rx For Pharma Boom Dec 02 2014

      Add Notes, Comments

      If you want to ask a question, or report a bug, please create a support ticket.

      User Comments

      No comment yet
      Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
      GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
      Free 7-day Trial
      FEEDBACK